Profile data is unavailable for this security.
About the company
Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.
- Revenue in CAD (TTM)0.00
- Net income in CAD-14.72m
- Incorporated2005
- Employees18.00
- LocationResverlogix Corp300-4820 Richard Rd SWCALGARY T3E 6L1CanadaCAN
- Phone+1 (403) 254-9252
- Fax+1 (403) 254-9252
- Websitehttps://www.resverlogix.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Medicure Inc | 20.93m | -2.63m | 9.60m | 25.00 | -- | 0.4914 | -- | 0.4587 | -0.2529 | -0.2529 | 1.94 | 1.87 | 0.7288 | 2.28 | 4.38 | 837,280.00 | -9.16 | -13.42 | -12.73 | -18.28 | 61.41 | 61.87 | -12.56 | -27.38 | 1.42 | -- | 0.0202 | -- | -5.94 | -5.71 | -167.55 | -- | -28.82 | -- |
Numinus Wellness Inc | 20.10m | -24.36m | 9.71m | -- | -- | 2.08 | -- | 0.4832 | -0.0906 | -0.0946 | 0.0752 | 0.0145 | 0.8572 | -- | 11.72 | -- | -103.89 | -77.31 | -129.39 | -84.20 | 30.80 | -- | -121.19 | -323.32 | -- | -13.08 | 0.6044 | -- | 256.95 | -- | 32.59 | -- | -- | -- |
Telo Genomics Corp | 0.00 | -2.97m | 11.98m | 8.00 | -- | 19.03 | -- | -- | -0.0434 | -0.0434 | 0.00 | 0.0084 | 0.00 | -- | -- | 0.00 | -323.36 | -85.03 | -407.98 | -113.86 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -33.66 | -- | 24.41 | -- |
Resverlogix Corp | 0.00 | -14.72m | 18.13m | 18.00 | -- | -- | -- | -- | -0.0565 | -0.0565 | 0.00 | -0.3845 | 0.00 | -- | -- | 0.00 | -138.80 | -- | -- | -- | -- | -- | -- | -- | 0.0459 | -0.8227 | -- | -- | -- | -- | -363.74 | -- | -- | -- |
COSCIENS Biopharma Inc | 6.19m | -17.28m | 19.04m | 21.00 | -- | 0.4385 | -- | 3.07 | -12.83 | -12.83 | 3.66 | 11.74 | 0.0936 | 1.74 | 6.35 | -- | -26.11 | -26.24 | -30.53 | -30.34 | 39.42 | 83.68 | -278.95 | -300.31 | 3.05 | -- | 0.0604 | -- | -20.25 | -30.06 | 27.17 | -- | 16.12 | -- |
Sirona Biochem Corp | -16.37k | -2.67m | 19.50m | -- | -- | -- | -- | -- | -0.0105 | -0.0105 | -0.00006 | -0.0134 | -0.0171 | -- | 1.61 | -- | -278.90 | -173.09 | -- | -383.49 | -- | -- | -- | -1,405.28 | -- | -5.73 | -- | -- | -94.82 | -51.37 | 28.52 | -- | -- | -- |